glp 1 mecanismo de ação 🧠Os agonistas dos receptores GLP-1 (GLP-1RAs) emergem como uma nova fronteira no tratamento da dor crônica e distúrbios de adição. Tradicionalmente indicados para diabetes tipo 2 e obesidade, esses agentes demonstram GLP-1 Mechanism of Action. Glucagon-like

This class also has the side effect of modest weight reduction and reduction of systolic blood pressure

Its main actions include: Stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner Suppressing glucagon release, which reduces hepatic glucose production Slowing gastric emptying, which moderates post-meal glucose spikes Promoting satiety through central nervous system pathways, thereby reducing appetite GIP is released by K-cells in the proximal small intestine and shares some functions with GLP-1, particularly in enhancing insulin secretion after meals

Still, these positive results can be enhanced when in combination with other drugs, such as metformin, which allows for an effective treatment plan with no increase in adverse symptoms usually seen with the treatment of semaglutide alone [121, 122, 125, 126]

These findings have significant implications for medical practice and point towards future research directions in this evolving field